Alzamend Neuro Announces It Has Contracted with Altasciences to Conduct a Phase I Relative Bioavailability Study for AL001 for Dementia Related to Alzheimer's Disease in September 2021
Proactive: Emyria Signs Pure CBD Agreement with U.S.-based Altasciences to Help Fast Track Registration
Proactive: Emyria to Accelerate FDA and TGA CBD Registration Programs with Altasciences Deal
Up Close and Personal with Dr. David Nguyen, MD, MBA
.custom-column-left-text {
float: left;
width: 50%;
padding-right: 10px;
}
.custom-column-right-text {
float: right;
width: 45%;
text-align:center;
}
@media only screen and (max-width: 600px) {
.custom-column-left-text,
.custom-column-right-text,
.custom-column-flc-ebook-text {
float:none;
width:80%;
margin:0 auto;
}
}
Dr.
Ethnobridging Supports Global Clinical Development
.custom-column-left-text {
float: left;
width: 50%;
padding-right: 10px;
}
.custom-column-right-text {
float: right;
width: 45%;
text-align:center;
}
@media only screen and (max-width: 600px) {
.custom-column-left-text,
.custom-column-right-text,
.custom-column-flc-ebook-text {
float:none;
width:80%;
margin:0 auto;
}
}
In our February 2021 blog we discussed protocol design concepts for ethnobridging in Phase I clinical trials.